Celgene has recruited an R&D executive as part of an organisational shake-up designed to tackle issues with its drug pipeline. Merck, MD, who worked with Alise Reicin on immuno-oncology drug Keytruda, has been brought in to lead mid- to late-stage drug development across Celgene’s portfolio. The appointment follows an audit in May which revealed that two-thirds of the firm’s R&D programmes had failed over the past five years, with only one in 20 programmes resulting in a marketed product.
Celgene has recruited an R&D executive as part of an organisational shake-up designed to tackle issues with its drug pipeline. Alise Reicin, MD, who worked with Merck on immuno-oncology drug Keytruda, has been brought in to lead mid- to late-stage drug development across Celgene’s portfolio. The appointment follows an audit in May which revealed that two-thirds of the firm’s R&D programmes had failed over the past five years, with only one in 20 programmes resulting in a marketed product.